Integrase Strand Transfer Inhibitors

bictegravir (BIC) Potential Low-Level Resistance

cabotegravir (CAB) Low-Level Resistance

dolutegravir (DTG) Potential Low-Level Resistance

elvitegravir (EVG) High-Level Resistance raltegravir (RAL)

Drug resistance interpretation: IN

Intermediate Resistance

R20K • T112A • T124A

IN comments

IN Other Mutations:

- E92Q is a common non-polymorphic mutation selected in persons receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It does not reduce susceptibility to BIC, CAB, and DTG.
- This virus is predicted to have low-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be relatively contraindicated.

Mutation scoring: IN

Drug resistance mutation scores of INSTI: Download CSV

Rule	BIC ÷	CAB ÷	DTG ÷	EVG ÷	RAL ÷
E92EQ	10	15	10	60	30

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)